Navigation Links
Auditors for Genta Incorporated Express Going Concern Qualification
Date:3/20/2008

BERKELEY HEIGHTS, N.J., March 20 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that in its 2007 financial statements included in the Company's Annual Report on Form 10-K, the auditor's opinion contained a "going concern" qualification. NASDAQ's marketplace rules require NASDAQ-listed companies to publicly announce the receipt of an audit opinion containing a "going concern" qualification.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at:

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genta Announces Senior Management Changes
2. Genta Announces Common Stock Offering of Approximately $3.1 Million
3. Genta Incorporated to Present at the BIO CEO & Investor Conference
4. Genta Receives Notice of Non-Compliance With NASDAQ Rule
5. Genta Receives NASDAQ Non-Compliance Notice
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
8. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
9. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
10. Syngenta Licenses Chromatin Gene Stacking Technology
11. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... a primary focus on the continued rapid development ... workforce reduction,of 52 employees, representing approximately 33% of ... Endo Pharmaceuticals, Inc. have agreed to,mutually terminate their ...
... enterprise accounting system across its US & China-based ... Alternext US: ADL), a vertically integrated pharmaceutical company ... today it is implementing a state-of-the-art, westernized enterprise ... , , Developed by ...
... Amicus Therapeutics (Nasdaq: FOLD ) will announce ... the regular close of markets on Thursday, February 5, ... live conference call and webcast that afternoon at 5 ... conference call at 5 p.m. EST by dialing 877-675-4756 ...
Cached Biology Technology:Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation 2Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation 3Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation 4AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 2AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 3AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market 4Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:4/22/2014)... the University of Montana,s Wildlife Biology Program, co-wrote a research ... National Academy of Sciences on how streamwater chemistry varies ... Lowe and ... of Washington, the Cary Institute of Ecosystem Studies, the University ... examined 664 water samples collected every 10 meters along 32 ...
(Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
(Date:4/22/2014)... expert will present a poster titled "A ... 7th International Nanotoxicology Congress to be held April ... Sharma will outline a strategy consistent with the 2007 ... Toxicity Testing in the 21st Century: A Vision and ... involving human cells and cell lines for mechanistic pathwaybased ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... Society of Interventional Radiology, an international organization of ... improving public health through minimally invasive, image-guided treatments, ... Veins" coalition, an alliance of organizations united to ... veins and chronic venous insufficiency. "Becoming part ...
... and deaths linked to those products are fostering new ... to the cover story in the current edition of ... of the American Chemical Society, the world,s largest scientific society. ... stories have surfaced with increasing frequency in recent years about ...
... the cross-country ski run. Things are looking good for him. Up ... best time. However, whether or not he finishes first is often ... must be right, including the conditions on the cross-country ski run, ... adapted custom-fit skis. In contrast to Olympic skiing stars who are ...
Cached Biology News:Society of Interventional Radiology: Time to rethink varicose veins 2Optimized custom-made ski sledges 2Optimized custom-made ski sledges 3
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... cDNA Labeling Kit with CyScribe GFX ... generation and purification of Cy3- and ... for complete cDNA labeling and purification.Flexible ... for performing labeling reactions with either ...
... CyScribe GFX Purification Kit, 24 reactions. ... Cy3- and Cy5-labeled cDNA.Optimized reagents are ... and purification.Flexible and optimized protocols can ... with either Cy3- or Cy5-labeled nucleotides.Reliable ...
Biology Products: